Abcam, ab266996, Human TRIM22 knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TRIM22 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 8 bp deletion in exon 3. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 8 bp deletion in exon 3,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TRIM22, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRIM22 also known as Staf50 is a protein encoded by the TRIM22 gene. It weighs approximately 56 kDa. TRIM22 is expressed in different tissues throughout the body including the spleen thymus and liver. This protein belongs to the tripartite motif (TRIM) family which is characterized by a distinct structure comprising a RING finger B-box domains and a coiled-coil region. The presence of a RING finger domain suggests that TRIM22 might have E3 ubiquitin ligase activity.
Biological function summary
TRIM22 plays a significant role in innate immunity influencing the antiviral response. As an E3 ubiquitin ligase it facilitates the ubiquitination and degradation of host proteins that are involved in viral replication processes. TRIM22 does not generally function in a protein complex but it interacts with other proteins in a cellular context. This interaction enhances the cellular response against viral infections by disrupting viral components and inhibiting viral replication.
Pathways
TRIM22 is involved in the IFN (interferon) signaling pathway which is essential for the immune response against pathogens. In this pathway TRIM22 interacts with proteins like IFNAR1 and STAT1 acting as a mediator of antiviral activities. It also participates in the ubiquitin-proteasome system aiding in the regulation of protein turnover within the cell. These pathways demonstrate the broad scope of TRIM22 in maintaining cellular homeostasis and responding to external immune challenges.
TRIM22 has been linked to conditions such as systemic lupus erythematosus (SLE) and certain cancers. In SLE TRIM22 expression is often dysregulated contributing to an altered immune response. The protein also connects with STAT proteins which can be influential in autoimmune disease pathways. Moreover aberrant expression of TRIM22 has been observed in some cancer types suggesting a role in tumor biology and potentially offering a target for therapeutic intervention.